C&Y Pharmaceutical(SZ:300254) Zheng Quan Zhi Xing·2025-08-08 11:14Core Viewpoint - Shanxi Qianyuan Pharmaceutical Group Co., Ltd. is implementing a 2025 restricted stock incentive plan, which has received necessary approvals and is in compliance with relevant laws and regulations [1][3][6]. Group 1: Legal Framework and Compliance - The law firm Grandall (Shanghai) has been appointed as the legal advisor for the company's 2025 restricted stock incentive plan, ensuring compliance with the Company Law, Securities Law, and other relevant regulations [1][2]. - The law firm has confirmed that the legal opinion provided is based on existing facts and applicable laws, and it will bear legal responsibility for the opinion issued [2][3]. Group 2: Approval Process - The approval process for the incentive plan included multiple meetings: the board meeting on July 21, 2025, where the draft plan was approved, and the shareholders' meeting on August 7, 2025, which also approved the plan [3][4]. - The board of directors held a subsequent meeting on August 8, 2025, to approve the first grant of restricted stocks to the incentive targets [4][6]. Group 3: Grant Details - The first grant of restricted stocks is set for August 8, 2025, with a total of 7.95 million shares to be granted to 171 eligible incentive targets at a price of 5.60 yuan per share [6][7]. - The granting conditions include compliance with specific financial and regulatory criteria, ensuring that the company meets the necessary standards for stock incentives [5][6]. Group 4: Conclusion - The law firm concludes that the incentive plan's first grant has obtained the required authorizations and approvals, and all conditions for granting the restricted stocks have been met [6][7].